BASF Closes Sale of Custom Synthesis Business
BASF completes sale of custom synthesis business and parts of its API business to Siegfried Holding.
BASF announced on Oct. 1. 2015 that the company had completed the sale of its pharma custom synthesis business and parts of its APIs business to Siegfried Holding AG.
Effective Oct. 1, Siegfried Holding AG assumed operational management of the businesses; about 850 employees transfer to Siegfried as part of the transaction. The enterprise value is approximately €270 million.
BASF will provide transitional services until late 2016, including sales and distribution of the divested API portfolio as non-exclusive distributor for Siegfried, BASF reports. The pharma custom synthesis business has been transferred in its entirety to Siegfried.
BASF reports the company is focusing its pharmaceutical ingredients and services business on its core expertise in pharmaceutical excipients. Selected APIs, such as ibuprofen, omega-3 fatty acids and polyethylenglycol, where the company has a leading market position, will remain part of BASF’s portfolio.
Source: BASF
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
